Recently, Novartis announced that its JAK inhibitor, Jakavi (Lusutinib phosphate tablets), has been approved for a new indication by the National Medical Products Administration (NMPA) in China for the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 and above who have unsatisfactory response to glucocorticoids or other systemic treatments. Prior to this, Lusutinib has been approved in China in 2023 for the treatment of acute GVHD (aGVHD) in patients aged 12 and above who have unsatisfactory response to glucocorticoids or other systemic treatments.
诺华磷酸芦可替尼片治疗慢性移植物抗宿主病新适应症在华获批
Novartis' Lusutinib phosphate tablets have been approved for a new indication in China for the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 and above who have unsatisfactory response to glucocorticoids or other systemic treat
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.